Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
13
|
pubmed:dateCreated |
1993-7-21
|
pubmed:abstractText |
Previous studies indicate that the heparinoid pentosan polysulfate (PPS) can inhibit heparin-binding growth factors (HBGFs) released from tumor cells and thus block tumor growth in animal models. However, because of its heparin-like activity, the major toxic effect expected for PPS is its inhibition of coagulation.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0027-8874
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
7
|
pubmed:volume |
85
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1068-73
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:7685831-Biological Assay,
pubmed-meshheading:7685831-Blood Coagulation,
pubmed-meshheading:7685831-Cell Division,
pubmed-meshheading:7685831-Growth Substances,
pubmed-meshheading:7685831-Humans,
pubmed-meshheading:7685831-Neoplasms,
pubmed-meshheading:7685831-Partial Thromboplastin Time,
pubmed-meshheading:7685831-Pentosan Sulfuric Polyester,
pubmed-meshheading:7685831-Reference Values,
pubmed-meshheading:7685831-Tumor Cells, Cultured
|
pubmed:year |
1993
|
pubmed:articleTitle |
Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate.
|
pubmed:affiliation |
V.T. Lombardi Cancer Research Center, Georgetown University Medical Center, Washington, D.C. 20007.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|